B. Riley Wealth Advisors Inc. Buys New Shares in Gilead Sciences, Inc. $GILD

B. Riley Wealth Advisors Inc. bought a new position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor bought 6,063 shares of the biopharmaceutical company’s stock, valued at approximately $672,000.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. Brighton Jones LLC increased its position in Gilead Sciences by 20.6% during the fourth quarter. Brighton Jones LLC now owns 14,359 shares of the biopharmaceutical company’s stock worth $1,326,000 after purchasing an additional 2,450 shares during the last quarter. Bison Wealth LLC acquired a new position in Gilead Sciences during the fourth quarter valued at approximately $215,000. Steward Partners Investment Advisory LLC grew its stake in Gilead Sciences by 11.1% during the first quarter. Steward Partners Investment Advisory LLC now owns 50,925 shares of the biopharmaceutical company’s stock worth $5,706,000 after buying an additional 5,107 shares during the period. Aptus Capital Advisors LLC increased its position in shares of Gilead Sciences by 2.0% in the first quarter. Aptus Capital Advisors LLC now owns 18,675 shares of the biopharmaceutical company’s stock worth $2,093,000 after acquiring an additional 374 shares in the last quarter. Finally, Colonial Trust Advisors lifted its holdings in shares of Gilead Sciences by 304.3% during the 1st quarter. Colonial Trust Advisors now owns 283 shares of the biopharmaceutical company’s stock valued at $32,000 after acquiring an additional 213 shares in the last quarter. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Gilead Sciences Price Performance

Shares of NASDAQ GILD opened at $118.78 on Wednesday. The company has a debt-to-equity ratio of 1.03, a current ratio of 1.45 and a quick ratio of 1.31. The firm has a market capitalization of $147.37 billion, a PE ratio of 18.42, a P/E/G ratio of 0.66 and a beta of 0.32. Gilead Sciences, Inc. has a 1-year low of $88.57 and a 1-year high of $128.70. The business’s fifty day moving average price is $122.06 and its two-hundred day moving average price is $115.93.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Thursday, October 30th. The biopharmaceutical company reported $2.47 earnings per share for the quarter, topping the consensus estimate of $2.16 by $0.31. The business had revenue of $7.77 billion during the quarter, compared to the consensus estimate of $7.42 billion. Gilead Sciences had a net margin of 27.88% and a return on equity of 51.86%. The company’s quarterly revenue was up 3.0% compared to the same quarter last year. During the same quarter in the prior year, the company posted $2.02 earnings per share. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. On average, research analysts expect that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, December 30th. Investors of record on Monday, December 15th will be paid a dividend of $0.79 per share. The ex-dividend date of this dividend is Monday, December 15th. This represents a $3.16 annualized dividend and a yield of 2.7%. Gilead Sciences’s dividend payout ratio is currently 48.99%.

Insider Buying and Selling

In other news, EVP Deborah H. Telman sold 53,646 shares of the stock in a transaction on Wednesday, November 12th. The stock was sold at an average price of $122.85, for a total transaction of $6,590,411.10. Following the completion of the sale, the executive vice president owned 43,676 shares in the company, valued at approximately $5,365,596.60. This represents a 55.12% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Daniel Patrick O’day sold 10,000 shares of Gilead Sciences stock in a transaction on Friday, November 28th. The stock was sold at an average price of $126.54, for a total value of $1,265,400.00. Following the completion of the transaction, the chief executive officer owned 571,203 shares in the company, valued at $72,280,027.62. The trade was a 1.72% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 136,257 shares of company stock valued at $16,723,492 in the last three months. Insiders own 0.27% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have commented on GILD. Needham & Company LLC raised their price objective on Gilead Sciences from $133.00 to $140.00 and gave the company a “buy” rating in a research report on Thursday, November 13th. Dbs Bank raised shares of Gilead Sciences to a “moderate buy” rating in a research report on Friday, September 5th. Rothschild & Co Redburn lifted their target price on Gilead Sciences from $143.00 to $153.00 in a research report on Monday, November 10th. TD Cowen boosted their price target on Gilead Sciences from $115.00 to $125.00 and gave the stock a “buy” rating in a research note on Thursday, October 23rd. Finally, Cantor Fitzgerald reissued an “overweight” rating and set a $135.00 price target on shares of Gilead Sciences in a research report on Friday, October 31st. Two research analysts have rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and four have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, Gilead Sciences presently has a consensus rating of “Moderate Buy” and an average price target of $131.54.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.